LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

2.38

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.25

Max

2.52

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+74.46% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	59M 711M
Eelmine avamishind	2.38
Eelmine sulgemishind	2.38

Uudiste sentiment

By Acuity

19%

81%

39 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11. mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11. mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11. mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11. mai 2026, 22:32 UTC

Tulu

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11. mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11. mai 2026, 21:49 UTC

Tulu

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11. mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11. mai 2026, 21:23 UTC

Omandamised, ülevõtmised, äriostud

CSG Systems Sale to NEC Gets CFIUS Clearance

11. mai 2026, 21:12 UTC

Tulu

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11. mai 2026, 21:12 UTC

Tulu

Ovintiv 1Q Loss/Shr $2.35 >OVV

11. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11. mai 2026, 20:44 UTC

Tulu

Steris: Board Approves New $1B Shr Repurchase Program >STE

11. mai 2026, 20:43 UTC

Tulu

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Rev $136.4M >CLSK

11. mai 2026, 20:30 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Cont Ops EPS $2.24 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Rev $1.6B >STE

11. mai 2026, 20:30 UTC

Tulu

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Adj EPS $2.83 >STE

11. mai 2026, 20:22 UTC

Kuumad aktsiad

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11. mai 2026, 19:37 UTC

Tulu

More Bad News at KKR's Private Credit Fund -- Barrons.com

11. mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

74.46% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 74.46%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

39 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.